Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | NLN | Q9BYT8 | 3/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11606914 | 1.00 | CYP3A4 (0.50) | CYP3A4SLC7A5DPP4DPP7NLN | |
| SCHEMBL1537285 | 0.80 | CYP3A4 (0.71) | CYP3A4SLC7A5 | |
| SCHEMBL163444 | 0.80 | CYP3A4 (0.71) | CYP3A4SLC7A5 | |
| SCHEMBL27273945 | 0.80 | CYP3A4 (0.50) | CYP3A4SLC7A5DPP4NLN | |
| Hydrochloric Acid SCHEMBL28331180 | 0.79 | CYP3A4 (0.69) | CYP3A4SLC7A5 | |
| SCHEMBL28328192 | 0.77 | CYP3A4 (0.67) | CYP3A4SLC7A5 | |
| SCHEMBL3726266 | 0.76 | CTSC (0.50) | CYP3A4SLC7A5DPP4DPP7 | |
| SCHEMBL2478803 | 0.76 | CTSC (0.50) | CYP3A4SLC7A5DPP4DPP7 | |
| SCHEMBL498386 | 0.76 | CTSC (0.50) | CYP3A4SLC7A5DPP4DPP7 | |
| SCHEMBL5221763 | 0.76 | CYP3A4 (0.65) | CYP3A4SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116333038-A | Aspirin derivative, preparation method and application thereof in preventing cardiovascular and cerebrovascular diseases | 湖北南博生物工程有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-111246859-B | Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component | 诺麦塔制药有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-111246859-A | Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component | 诺麦塔制药有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-101674842-A | Compositions and methods for treating alzheimer's disease and dementia | PREVENTIVE NUTRIENT COMPANY IN | 2010-03-17 | — | — | CN | claimed |
| WO-2003099322-A2 | IL-11 DERIVATIVES AND THERAPEUTIC USES THEREOF | ISIS INNOVATION LIMITED (GB) | 2003-12-04 | — | — | WO | claimed |
| CN-116803290-A | Meat processing method capable of reducing content of bound heterocyclic amine | 江南大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-116333038-A | Aspirin derivative, preparation method and application thereof in preventing cardiovascular and cerebrovascular diseases | 湖北南博生物工程有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116333038-A | Aspirin derivative, preparation method and application thereof in preventing cardiovascular and cerebrovascular diseases | 湖北南博生物工程有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-111246859-B | Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component | 诺麦塔制药有限公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3684332-A1 | VEGFR-FC FUSION PROTEIN FORMULATIONS | Amgen Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| CN-111246859-A | Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component | 诺麦塔制药有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-3502699-A1 | METHODS FOR DIAGNOSING PANCREATIC CANCER | Metanomics Health GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| WO-2002064621-A3 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON LLC (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002064621-A3 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON LLC (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030082740-A1 | Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent | ATTENUON, LLC | 2003-05-01 | — | — | US | disclosed |
| US-20030082740-A1 | Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent | ATTENUON, LLC | 2003-05-01 | — | — | US | disclosed |
| US-20030082740-A1 | Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent | ATTENUON, LLC | 2003-05-01 | — | — | US | disclosed |
| WO-2002064621-A2 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON, LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064621-A2 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON, LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064621-A2 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON, LLC (US) | 2002-08-22 | — | — | WO | disclosed |